Cancer Vaccine Market Set to Hit 36% CAGR as mRNA Breakthroughs Expand Beyond Melanoma

Key points

• The cancer therapeutic vaccine market reached approximately $335 million in 2025, with the United States accounting for 87% of the total in the seven major markets.
• Prostate cancer represents the largest patient pool with 2.8 million cases in 2025, while melanoma, breast cancer, and lung cancer are identified as the fastest-growing segments.
• Moderna and Merck’s intismeran autogene achieved a landmark Phase 3 result in August 2026, showing improved recurrence-free survival in melanoma when combined with Keytruda.
• The FDA granted accelerated approval in August 2026 to vusolimogene oderparepvec for advanced melanoma, and Candel Therapeutics is preparing a BLA submission for its prostate cancer vaccine in Q4 2026.
• Market growth is fueled by advances in mRNA technology, personalized neoantigen identification, and the shift toward combination therapies with immune checkpoint inhibitors.

Background

In August 2026, Moderna’s stock surged approximately 177% following the announcement that its personalized mRNA cancer vaccine, intismeran autogene, significantly reduced melanoma recurrence in a Phase 3 trial. This breakthrough marked a pivotal moment for the biotech sector, shifting focus from infectious disease vaccines to oncology. Analysts from major banks highlighted the potential for label expansions into other solid tumors, though questions remained regarding the commercial viability and broader applicability of the 'market-of-one' approach. The current market forecast builds on this momentum, projecting sustained growth as these therapies move from experimental status to established clinical standards.

How outlets are covering it

DelveInsight and Healthcare Asia Magazine emphasize the quantitative market expansion, citing a 36% CAGR and the dominance of the US market. They highlight the diversification of indications beyond melanoma, particularly into prostate and lung cancer. The Washington Post focuses on the technological implications, framing the melanoma success as a catalyst for a wave of new mRNA treatments across various cancers. While DelveInsight notes a gap between immunogenicity and late-stage outcomes, The Washington Post presents a more optimistic view regarding the potential for rapid adoption of personalized vaccines. All sources agree on the significance of the August 2026 Phase 3 results but differ in their emphasis on market size versus clinical breakthrough potential.

Why it matters

The success of personalized cancer vaccines signals a shift in oncology treatment paradigms, moving from broad immunotherapies to highly targeted, individualized approaches. This could redefine revenue models for biotech firms like Moderna and Merck, while offering new hope for patients with solid tumors. The rapid expansion of the pipeline and regulatory approvals indicate that cancer vaccines are transitioning from experimental therapies to standard care, potentially altering the competitive landscape in the multi-billion dollar immunotherapy market.

What to watch

Investors and clinicians should monitor the Q4 2026 BLA submission by Candel Therapeutics for its prostate cancer vaccine and the ongoing Phase 3 trials for intismeran autogene in non-small cell lung cancer. The market will also watch for the commercialization of vusolimogene oderparepvec and the potential expansion of Moderna’s vaccine into earlier-stage disease settings. Regulatory decisions on these candidates will determine the pace of market growth and the extent to which personalized vaccines become a standard of care across multiple cancer types.